Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

VNDA

Vanda Pharmaceuticals Inc

Feb 13 • 03:47PM ET

6.09

-0.03 -0.57 %

Healthcare • Biotechnology • USA • NASD

Feb 12, 2:27 AMVanda Pharmaceuticals posts Q4 miss with revenue $57.2M (+8% YoY) and non-GAAP EPS -$2.39; full-year revenue rose 9% to $216.1M while recording a $113.7M non-cash tax charge. FDA approves NEREUS, and with Fanapt driving double-digit growth the company raises 2026 revenue guidance for currently marketed products to $230–$260M.

Peers: NBIX SAGE XENE ACAD ITCI PRTA MDGL KURA ARDX EPIX

| Held by: VTI IWM VXF IWN IBB VTWO SCHA VHT DFAS FESM

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-3.74	Insider Own	6.79%	Shs Outstand	59.10M	Perf Week	-19.62%
Market Cap	359.60M	Forward P/E	-	EPS next Y	-0.82	Insider Trans	0.00%	Shs Float	55.08M	Perf Month	-20.97%
Enterprise Value	102.82M	PEG	-	EPS next Q	-0.64	Inst Own	77.54%	Short Float	5.85%	Perf Quarter	37.98%
Income	-220.47M	P/S	1.66	EPS this Y	52.14%	Inst Trans	1.49%	Short Ratio	1.82	Perf Half Y	37.36%
Sales	216.10M	P/B	0.77	EPS next Y	54.00%	ROA	-38.51%	Short Interest	3.22M	Perf YTD	-31.01%
Book/sh	7.89	P/C	1.36	EPS next 5Y	65.52%	ROE	-50.93%	52W High	9.60 -36.61%	Perf Year	29.47%
Cash/sh	4.46	P/FCF	-	EPS past 3/5Y	- -	ROIC	-65.96%	52W Low	3.81 59.74%	Perf 3Y	-15.72%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-5.29% -2.73%	Gross Margin	94.33%	Volatility	7.51% 6.01%	Perf 5Y	-66.62%
Dividend TTM	-	EV/Sales	0.48	EPS Y/Y TTM	-1049.63%	Oper. Margin	-69.95%	ATR (14)	0.49	Perf 10Y	-23.36%
Dividend Ex-Date	-	Quick Ratio	2.38	Sales Y/Y TTM	8.72%	Profit Margin	-102.02%	RSI (14)	33.84	Recom	1.50
Dividend Gr. 3/5Y	- -	Current Ratio	2.39	EPS Q/Q	-2737.29%	SMA20	-19.29%	Beta	0.62	Target Price	13.62
Payout	-	Debt/Eq	0.02	Sales Q/Q	7.58%	SMA50	-15.55%	Rel Volume	0.59	Prev Close	6.12
Employees	368	LT Debt/Eq	0.02	Earnings	Feb 11 AMC	SMA200	14.60%	Avg Volume	1.77M	Price	6.09
IPO	Apr 12, 2006	Option/Short	Yes / Yes	EPS/Sales Surpr.	-145.13% -3.47%	Trades		Volume	1,014,101	Change	-0.57%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-05-25	Initiated	B. Riley Securities	Buy	$11
Oct-31-24	Initiated	H.C. Wainwright	Buy	$18
Jul-11-24	Initiated	Cantor Fitzgerald	Overweight	$11
Feb-25-22	Downgrade	Jefferies	Buy → Hold	$24 → $12
May-12-21	Initiated	BofA Securities	Buy	$22
Jan-14-21	Downgrade	Citigroup	Buy → Neutral	$14
Oct-29-20	Upgrade	Citigroup	Neutral → Buy	$14
Jun-09-20	Downgrade	Citigroup	Buy → Neutral	$14
Mar-16-20	Downgrade	Oppenheimer	Perform → Underperform
Mar-12-20	Upgrade	Citigroup	Neutral → Buy	$14
Nov-07-19	Downgrade	Citigroup	Buy → Neutral	$19
Aug-01-19	Upgrade	Citigroup	Neutral → Buy	$19
Jul-25-19	Downgrade	Stifel	Buy → Hold	$26 → $17
Dec-11-18	Downgrade	Oppenheimer	Outperform → Perform
Dec-04-18	Upgrade	Cantor Fitzgerald	Neutral → Overweight
Dec-04-18	Reiterated	Jefferies	Buy	$30 → $40
Nov-08-18	Resumed	Jefferies	Buy
Sep-21-18	Resumed	Oppenheimer	Outperform
May-23-18	Initiated	Citigroup	Buy	$26
Jan-19-18	Initiated	Seaport Global Securities	Buy	$20

Show Previous Ratings

Feb-12-26 08:08PM	Vanda Pharmaceuticals Inc. Q4 2025 Earnings Call Summary (Moby) -17.63%
12:02AM	Vanda Pharmaceuticals Inc (VNDA) Q4 2025 Earnings Call Highlights: Revenue Growth Amid Rising Losses (GuruFocus.com)
Feb-11-26 06:02PM	Vanda Pharmaceuticals Q4 Earnings Call Highlights (MarketBeat)
05:15PM	Vanda Pharmaceuticals (VNDA) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
04:21PM	Vanda: Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	Loading…
04:01PM	Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results (PR Newswire)
Feb-10-26 05:10PM	Gilead Sciences (GILD) Surpasses Q4 Earnings and Revenue Estimates (Zacks)
Feb-04-26 06:01PM	Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results on February 11, 2026 (PR Newswire) -5.59%
Jan-28-26 07:35AM	Intellia Therapeutics (NTLA) Surges 6.3%: Is This an Indication of Further Gains? (Zacks)
Jan-13-26 09:55AM	Vanda (VNDA) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now (Zacks)
Jan-08-26 07:00AM	Vanda Pharmaceuticals Announces Receipt of FDA Decision Letter on HETLIOZ Supplemental New Drug Application for Jet Lag Disorder (PR Newswire) -14.05%
Jan-01-26 08:25AM	Vanda Pharmaceuticals price target raised to $14 from $11 at B. Riley (TipRanks)
Dec-31-25 04:34PM	Stocks Settle Lower on Tech Weakness and Higher Bond Yields (Barchart) +25.46% -6.46%
11:12AM	These Stocks Are Moving the Most Today: Nvidia, Tesla, Hecla, Newmont, Nike, Vanda, Corcept, DJT, and More (Barrons.com)
10:57AM	Vanda Jumps 21% After FDA Approves Motion Sickness Therapy (GuruFocus.com)
10:57AM	Loading…
10:57AM	Vanda Pharmaceuticals Shares Jump 30% on Motion Sickness Drug Approval (Barrons.com)
09:57AM	Stocks Slide on Weakness in Megacap Tech Stocks (Barchart)
09:54AM	Biggest Mover Wednesday: Vanda's FDA Win Sends the Stock Flying (GuruFocus.com)
07:36AM	VNDA Obtains FDA Nod for Motion Sickness Drug, Stock Gains (Zacks)
Dec-30-25 06:13PM	Vanda Pharmaceuticals Announces FDA Approval of NEREUS (tradipitant) for the Prevention of Vomiting Induced by Motion: A Historic Scientific Milestone in the Prevention of Motion Sickness (PR Newswire)
Dec-29-25 09:13AM	3 Biotech Stocks With Major 2026 Catalysts (Zacks)
Dec-26-25 02:56PM	Christmas Week Brings S&P 500 Records, Tech Volatility (Schaeffer's Research)
11:41AM	Vanda Pharmaceuticals Stock Rallies on FDA Filing (Schaeffer's Research)
Dec-15-25 07:00AM	Vanda Announces Submission of Biologics License Application to the FDA for Imsidolimab for the Treatment of Generalized Pustular Psoriasis (PR Newswire) +6.42%
Dec-11-25 05:02PM	Vanda Pharmaceuticals Announces Participation in the J.P. Morgan Healthcare Conference (PR Newswire) -5.61%
Dec-04-25 04:21PM	FDA Lifts Partial Clinical Hold on Tradipitant for Motion Sickness (PR Newswire)
Nov-30-25 09:53AM	Should You Invest in This Under-the-Radar Weight Loss Stock? (Motley Fool)
Nov-28-25 07:00AM	Vanda Pharmaceuticals Provides Regulatory Update on Tradipitant for Motion Sickness (PR Newswire)
Nov-19-25 10:06AM	VNDA Stock Jumps on Upbeat Tradipitant Data Cutting GLP-1 Side Effects (Zacks)
05:33AM	Alkermes escalates bidding war; US biotech risks falling behind China (BioPharma Dive)
06:37PM	Loading…
Nov-17-25 06:37PM	Vanda Pharmaceuticals Reports Positive Results for Tradipitant in Preventing GLP-1 Induced Nausea and Vomiting (PR Newswire) +21.59%
Nov-05-25 05:00PM	Vanda Pharmaceuticals Announces Participation in the Stifel 2025 Healthcare Conference (PR Newswire)
09:51AM	Pinterest downgraded, Tractor Supply upgraded: Wall Street's top analyst calls (The Fly)
Oct-29-25 05:20PM	Vanda Pharmaceuticals (VNDA) Reports Q3 Loss, Misses Revenue Estimates (Zacks) -20.15%
04:18PM	Vanda: Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	Vanda Pharmaceuticals Reports Third Quarter 2025 Financial Results (PR Newswire)
Oct-28-25 12:02PM	Jim Cramer on Vanda Pharmaceuticals: "I'm Going to Bless That One as Your Spec" (Insider Monkey)
Oct-22-25 04:30PM	Vanda Pharmaceuticals to Announce Third Quarter 2025 Financial Results on October 29, 2025 (PR Newswire)
Oct-08-25 08:00AM	Monumental Sports & Entertainment Taps D.C.'s Own Vanda Pharmaceuticals as Founding Partner to Help Drive the Creation of Brand-New Downtown Arena (PR Newswire)
Oct-01-25 05:02PM	Vanda Pharmaceuticals Announces Collaborative Framework for Resolution of Disputes with the U.S. Food and Drug Administration (PR Newswire)
Sep-25-25 08:00AM	Vanda Pharmaceuticals announces the publication in PLOS One of an article titled "Melatonin agonist tasimelteon (HETLIOZ) improves sleep in patients with primary insomnia: A multicenter, randomized, double-blind, placebo-controlled trial" (PR Newswire)
Aug-28-25 05:23PM	Vanda Pharmaceuticals Announces Participation at September 2025 Investor Conferences (PR Newswire)
07:00AM	Vanda Pharmaceuticals Announces FDA Granted Orphan Drug Designation for VGT-1849B, a Novel and Selective Candidate for the Treatment of Polycythemia Vera (PR Newswire)
Aug-18-25 07:00AM	In a Major Win for Vanda, a Federal Appeals Court Overturns FDA's Order Denying Approval of Hetlioz for the Treatment of Jet Lag Disorder (PR Newswire)
Jul-31-25 08:40AM	Vanda Pharmaceuticals (VNDA) Reports Q2 Loss, Misses Revenue Estimates (Zacks) -8.78%
07:37AM	Vanda: Q2 Earnings Snapshot (Associated Press Finance)
07:30AM	Vanda Pharmaceuticals Reports Second Quarter 2025 Financial Results (PR Newswire)
Jul-30-25 05:15PM	Sage Therapeutics, Inc. (SAGE) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
Jul-23-25 04:45PM	Vanda Pharmaceuticals to Announce Second Quarter 2025 Financial Results on July 31, 2025 (PR Newswire)
Jul-18-25 07:24AM	Legend Biotech (LEGN) Surges 6.0%: Is This an Indication of Further Gains? (Zacks)
Jun-10-25 08:00AM	Vanda Pharmaceuticals Announces First Patient Dosed in a Trial Evaluating VCA-894A in Charcot-Marie-Tooth disease Type 2S (PR Newswire)
May-27-25 09:00AM	Vanda Pharmaceuticals Announces Presentation at 2025 ASCP Annual Meeting (PR Newswire)
May-16-25 05:30PM	Vanda Pharmaceuticals Announces Participation in the Mizuho Neuro & Ophthalmology Summit 2025 (PR Newswire) +5.85%
May-08-25 08:04AM	Q1 2025 Vanda Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
03:28AM	Vanda Pharmaceuticals Inc (VNDA) Q1 2025 Earnings Call Highlights: Revenue Growth Amid Rising ... (GuruFocus.com)
May-07-25 07:56PM	Vanda pharmaceuticals outlines $210M-$250M revenue target for 2025 amid product launches (Seeking Alpha)
07:55PM	Vanda Pharmaceuticals Inc. (VNDA) Q1 2025 Earnings Call Transcript (Seeking Alpha)
05:10PM	Vanda Pharmaceuticals (VNDA) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:07PM	Vanda: Q1 Earnings Snapshot (Associated Press Finance)
04:01PM	Vanda Pharmaceuticals Reports First Quarter 2025 Financial Results (PR Newswire)
May-05-25 08:00AM	Vanda Announces Bysanti NDA Filing; FDA Decision Expected in Early 2026 (PR Newswire)
May-02-25 08:46AM	Vanda Pharmaceuticals to Announce First Quarter 2025 Financial Results on May 7, 2025 (PR Newswire)
May-01-25 05:35PM	Tarsus Pharmaceuticals, Inc. (TARS) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
Apr-28-25 04:00AM	FDAs job cuts paint mixed picture for drugmakers R&D plans (Pharma Voice)
Apr-25-25 06:34AM	Halozyme sues Merck; FDA blames cuts for Vanda delay (BioPharma Dive)
Apr-23-25 03:52PM	FDA Bureaucrats Unlawfully Delay Hearing on Vanda Drug and Falsely Blame Commissioner Makary and the reductions in force at FDA (PR Newswire)
Apr-07-25 02:21PM	Vanda Pharmaceuticals: Financials Are Great, But Market Reaction Is Confusing (Seeking Alpha)
08:00AM	Vanda Pharmaceuticals Announces Presentation at 2025 AAN Annual Meeting (PR Newswire)
Mar-31-25 08:00AM	Vanda Pharmaceuticals Announces the Submission of an NDA to the FDA for Bysanti for the Treatments of Acute Bipolar I Disorder and Schizophrenia (PR Newswire)
Feb-24-25 07:00AM	Vanda Pharmaceuticals announces the publication of an article titled 'Potential ASO-based personalized treatment for Charcot-Marie-Tooth disease type 2S' (PR Newswire)
Feb-14-25 09:41AM	Q4 2024 Vanda Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents) -5.96%
02:20AM	Vanda Pharmaceuticals Inc (VNDA) Q4 2024 Earnings Call Highlights: Revenue Growth Amidst Challenges (GuruFocus.com)
Feb-13-25 05:15PM	Vanda Pharmaceuticals (VNDA) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
04:18PM	Vanda: Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results (PR Newswire)
Feb-05-25 04:30PM	Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2024 Financial Results on February 13, 2025 (PR Newswire)
Feb-04-25 06:37AM	Vanda and AnaptysBio link for generalised pustular psoriasis therapy (Pharmaceutical Technology)
Feb-03-25 07:30AM	Vanda Pharmaceuticals and Anaptys Announce Exclusive Global License Agreement for Vanda to Develop and Commercialize Imsidolimab, an IL-36R Antagonist (PR Newswire)
Jan-29-25 05:39AM	BioAge drops obesity drug; Akero, 89bio cash in on MASH data (BioPharma Dive)
Jan-27-25 07:00AM	Vanda Pharmaceuticals Accepts FDA Opportunity for a Hearing on New Drug Application for Tradipitant in Gastroparesis (PR Newswire)
Jan-16-25 01:47PM	FDA Unveils Grounds For Rejecting Vanda Pharmaceuticals Stomach Paralysis Candidate (Benzinga)
Jan-08-25 04:17PM	Vanda's Letter to FDA Commissioner Highlights Faulty Gastroparesis NDA Review (PR Newswire)
Dec-20-24 09:13AM	Vanda Pharmaceuticals Announces Orphan Drug Designation Granted for VGT-1849A, a Novel and Selective Antisense Oligonucleotide Candidate for the Treatment of Polycythemia Vera (PR Newswire)
Nov-12-24 04:58PM	Vanda Pharmaceuticals Announces Participation at November 2024 Investor Conferences (PR Newswire)
Nov-07-24 02:21AM	Vanda Pharmaceuticals Inc (VNDA) Q3 2024 Earnings Call Highlights: Revenue Surge Amidst Rising ... (GuruFocus.com)
Nov-06-24 04:12PM	Vanda: Q3 Earnings Snapshot (Associated Press Finance)
04:02PM	Vanda Pharmaceuticals Reports Third Quarter 2024 Financial Results (PR Newswire)
Nov-01-24 02:05PM	Over 200% Stock Upside - Vanda Pharmaceuticals Undervalued With Robust Portfolio And Pipeline: Analyst (Benzinga)
Oct-31-24 12:27PM	Health Care Roundup: Market Talk (The Wall Street Journal)
Oct-30-24 04:30PM	Vanda Pharmaceuticals to Announce Third Quarter 2024 Financial Results on November 6, 2024 (PR Newswire)
Oct-15-24 08:30AM	Cycle Pharmaceuticals reaffirms proposal to acquire Vanda Pharmaceuticals (TipRanks)
Oct-14-24 12:08PM	Cycle Pharmaceuticals Stands By $488 Million Offer for Vanda (Bloomberg) +8.33%
10:56AM	Vanda Pharmaceuticals Confirms Receipt of Economically Identical Unsolicited, Non-Binding Proposal from Cycle Group Holdings Ltd. (PR Newswire)
10:37AM	Vanda Pharmaceuticals rejects Cycle Pharma's second takeover offer (Reuters)
08:19AM	Cycle Pharmaceuticals Reaffirms All-Cash Proposal to Acquire Vanda Pharmaceuticals for $8.00 Per Share (Business Wire)
Sep-20-24 07:28AM	Novo sinks on obesity drug results; Sanofi reveals anticipated MS data (BioPharma Dive)
06:12AM	FDA declines approval of Vandas gastroparesis treatment (Pharmaceutical Technology)
Sep-19-24 05:20PM	Why Vanda Pharmaceuticals Stock Sank by Nearly 6% Today (Motley Fool) -6.06%
07:00AM	FDA Declines to Approve Vanda's Marketing Application for Tradipitant in Gastroparesis (PR Newswire)
Sep-11-24 05:00PM	Vanda Pharmaceuticals Announces Participation in the 2024 Cantor Global Healthcare Conference (PR Newswire)

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Polymeropoulos Mihael Hristos	President and CEO	Aug 07 '25	Buy	4.15	10,000	41,500	2,335,731	Aug 08 04:05 PM
Mitchell Stephen Ray	Director	Jun 13 '25	Sale	4.59	7,000	32,130	97,082	Jun 16 09:10 PM
Mitchell Stephen Ray	Director	Jun 13 '25	Proposed Sale	4.59	7,000	32,159		Jun 13 09:40 PM
Polymeropoulos Mihael Hristos	President and CEO	May 21 '25	Buy	4.40	10,000	43,995	2,325,731	May 21 09:23 PM
Polymeropoulos Mihael Hristos	President and CEO	May 16 '25	Buy	4.22	20,000	84,472	2,315,731	May 19 05:13 PM
Polymeropoulos Mihael Hristos	President and CEO	Mar 06 '25	Buy	5.01	10,000	50,150	2,295,731	Mar 06 05:53 PM
Polymeropoulos Mihael Hristos	President and CEO	Mar 05 '25	Buy	5.02	10,000	50,200	2,285,731	Mar 05 05:19 PM
Polymeropoulos Mihael Hristos	President and CEO	Mar 03 '25	Buy	4.71	10,000	47,050	2,275,731	Mar 04 04:45 PM
Polymeropoulos Mihael Hristos	President and CEO	Feb 28 '25	Buy	4.76	10,000	47,600	2,361,730	Feb 28 05:30 PM
Polymeropoulos Mihael Hristos	President and CEO	Feb 27 '25	Buy	4.76	10,000	47,600	2,351,730	Feb 27 04:13 PM
Polymeropoulos Mihael Hristos	President and CEO	Feb 26 '25	Buy	4.76	10,000	47,650	2,341,730	Feb 26 04:46 PM
Polymeropoulos Mihael Hristos	President and CEO	Feb 25 '25	Buy	4.46	10,000	44,640	2,331,730	Feb 25 07:38 PM
Moran Kevin Patrick	SVP, CFO & Treasurer	Feb 21 '25	Buy	4.39	2,000	8,779	355,763	Feb 24 07:04 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

VNDA

Vanda Pharmaceuticals Inc

Upgrade your FINVIZ experience